Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1764-1766
Number of pages3
JournalLeukemia and Lymphoma
Volume58
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Cite this